Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zatolmilast - Tetra Therapeutics

Next Previous
Drug Profile

Zatolmilast - Tetra Therapeutics

Alternative Names: BPN-14770

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tetra Discovery Partners
  • Developer Tetra Therapeutics
  • Class Acetamides; Amines; Antidementias; Benzeneacetamides; Chlorobenzenes; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Cognition disorders

Highest Development Phases

  • Phase II/III Fragile X syndrome
  • Phase II Alzheimer's disease

Most Recent Events

  • 12 Jun 2025 Shionogi Inc plans to initiate a phase I trial for Hepatic Impairment (In healthy volunteers) in the US (PO) (NCT07018492)
  • 10 Jun 2025 Shionogi plans pharmacokinetics phase I trial (In healthy volunteers, In adults) (PO) (NCT07011992)
  • 03 Jun 2025 Shionogi plans phase-I pharmacokinetics (PK) and safety trial in USA (PO) (NCT07012005)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top